Details for Patent: 9,227,946
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,227,946 protect, and when does it expire?
Patent 9,227,946 protects TRINTELLIX and is included in one NDA.
This patent has ninety-one patent family members in thirty-three countries.
Summary for Patent: 9,227,946
Title: | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Abstract: | 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT.sub.3 and 5-HT.sub.1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients. |
Inventor(s): | Faldt; Andre (Ishoj, DK), Holm; Rene (Jyllinge, DK), de Diego; Heidi Lopez (Naerum, DK) |
Assignee: | H. Lundbeck A/S (Copenhagen-Valby, DK) |
Application Number: | 14/242,337 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,227,946 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,227,946
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-001 | Sep 30, 2013 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER | See Plans and Pricing | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-002 | Sep 30, 2013 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER | See Plans and Pricing | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,227,946
International Family Members for US Patent 9,227,946
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 061481 | See Plans and Pricing | |||
Argentina | 065797 | See Plans and Pricing | |||
Austria | 495745 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |